Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IMAC Holdings's gross profit for the
three
months ended in Sep. 2025 was $-0.10 Mil. IMAC Holdings's gross profit for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.42 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. IMAC Holdings's gross profit for the
three
months ended in Sep. 2025 was $-0.10 Mil. IMAC Holdings's Revenue for the
three
months ended in Sep. 2025 was $0.02 Mil. Therefore, IMAC Holdings's Gross Margin % for the quarter that ended in Sep. 2025 was -490.48%.
IMAC Holdings had a gross margin of -490.48% for the quarter that ended in Sep. 2025 => No sustainable competitive advantage
During the past 9 years, the highestGross Margin % of IMAC Holdings was 91.98%. The lowest was -1817.39%. And the median was 86.06%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
IMAC Holdings had a gross margin of -490.48% for the quarter that ended in Sep. 2025 => No sustainable competitive advantage
IMAC Holdings Gross Profit Related Terms
IMAC Holdings Gross Profit Historical Data
* Premium members only.
The historical data trend for IMAC Holdings's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BACK vs FCHS, NHLG, PAIYY: Gross Profit Comparison
For the Medical Care Facilities subindustry, IMAC Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IMAC Holdings Gross Profit vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, IMAC Holdings's Gross Profit distribution charts can be found below:
* The bar in red indicates where IMAC Holdings's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.42 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
IMAC Holdings (BACK) has a Gross Profit of $-0.42 Mil as of Sep. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on IMAC Holdings and its competitors.
Is IMAC Holdings' Gross Profit too high?
IMAC Holdings' current Gross Profit is $-0.42 Mil.
How does IMAC Holdings' Gross Profit compare to FCHS and NHLG?
IMAC Holdings' Gross Profit of $-0.42 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Healthcare Providers & Services company?
A good Gross Profit depends on the Healthcare Providers & Services industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on IMAC Holdings and its competitors. IMAC Holdings's current Gross Profit is $-0.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IMAC Holdings stock overvalued right now?
IMAC Holdings (BACK) has a current Gross Profit of $-0.42 Mil. The current Gross Profit is $-0.42 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For IMAC Holdings (BACK), the current Gross Profit is $-0.42 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BACK has been successfully added to your 
